Oxiracetam Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Oxiracetam evidence and protocol review

Nootropic Compounds compound PowderCapsule verified

Also known as: 4-Hydroxy-2-oxopyrrolidine-N-acetamide

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

1 g, 5 g, 10 g

Storage

Use product-specific tablet or powder stability documentation; no U.S.-approved product storage standard applies

Solubility

Water-soluble

Catalog Description

Oxiracetam is a racetam nootropic studied for AMPA receptor modulation, acetylcholine and glutamate neurotransmission enhancement, and protein kinase C (PKC) activation, investigated for spatial-learning improvement and neuroprotection in hippocampal models. It is grouped among the first-class racetam compounds (with piracetam, aniracetam, and phenylpiracetam) explored as cognitive-enhancement add-ons, sharing the class's partially characterized mechanism and mixed clinical evidence quality.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Do not assign a universal half-life from secondary nootropic references; pharmacokinetics can vary with renal function and study population

Onset

Preclinical/clinical cognitive studies typically assess outcomes over weeks

Administration Routes (Research)

Oral in the cited human trials

Reported Research Effects

AMPA receptor modulation
Acetylcholine/glutamate neurotransmission enhancement
PKC activation (proposed mechanism)

Reported Research Side Effects

Unwanted effects occurred in four oxiracetam participants in the 12-week study
Two withdrawals for poor tolerability
One transient ischemic attack was judged unrelated
Modern long-term efficacy evidence remains limited

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

800 mg twice daily for 12 weeks [Oral; Multicenter double-blind placebo-controlled dementia study; Twice daily]Source: PMID 1414239
800 mg twice daily for 36 weeks [Oral; Multicenter randomized phase-IV post-stroke cognitive-impairment study; Twice daily]Source: PMID 36724841

Research Notes

These are indication-specific oral clinical regimens, not evidence for healthy-person cognitive enhancement.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Oxiracetam dementia randomized study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/1414239/

Oxiracetam vascular cognitive impairment phase-IV protocol — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/36724841/

Oxiracetam post-stroke multicenter randomized trial results — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/40882961/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.